Demonstrates real-time monitoring of trastuzumab in cancer treatment, highlighting potential for personalized dosing.
The real-time monitoring of trastuzumab (Tmab), a monoclonal antibody used for cancer treatment, is critical for personalized, response-guided dosing and improved biomanufacturing quality control. Currently, Tmab concentrations are quantified using immunoassays and mass spectrometry, but these platforms provide only discrete measurements and require extensive sample preparation. Surface-tethered electrochemical aptamer-based (E-AB) sensors provide a unique alternative because they operate without free-floating reagents, enable continuous measurements, and can be engineered to achieve high sensitivity and specificity. However, using E-AB sensors to detect macromolecules such as antibodies, rather than small molecules, requires careful consideration of surface-induced steric hindrance effects. In this work, we present a surface-functionalized Tmab-targeting E-AB sensor with optimized surface density and square-wave voltammetry frequency. The Tmab E-AB sensor employs a linked displacement strand construct and achieves K D = 70.8 nM and LoD = 0.66 nM at an estimated surface density of 15 molecules/mm 2 × 10 −9 . We further study the use of active and passive refresh techniques to enable continuous and quasi-continuous monitoring and demonstrate direct sensing in human serum and cell culture media.
No takes yet. Share an insight, caveat, or question.
Foo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: